AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06464198 — intervention group
Intervention type: PROCEDURE
Intervention: simultaneous postoperative radiochemotherapy
Description: The efficacy and tolerability of simultaneous postoperative radiochemotherapy is being investigated.
Study NCT05186688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Braining
Description: Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan.
Study NCT03994965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 milligrams (MG) [Nuplazid]
Description: Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
Study NCT05981482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OxVPS
Description: Comparing a new screening tool, the Oxford visual perception screening, to the gold standard, Rivermead Perceptual Battery Assessment.
Study NCT05659368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: tirzepatide once weekly
Study NCT05936398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscle Training - VIH
Description: The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
Study NCT05936398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscle Training - ITPL
Description: The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
Study NCT06440941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chatbot-based mindfulness-based stress reduction
Description: During the intervention, participants will be involved in a developed chatbot and undergo a single-item assessment to verify the stability of their mental states for subsequent mindfulness-based stress reduction (MBSR) sessions, deemed stable if rated as excellent, very good, or good; They will then engage in conversations with the chatbot, responding to prompts like What is the most recent thing that made you happy? to foster interactive communication and relaxation. Subsequently, participants need to follow guided MBSR sessions and are encouraged to interact with the chatbot for at least one hour daily; all interactions will be monitored and recorded. After eight weeks, a post-intervention assessment will be conducted, followed by pre-post statistical analyses. A total of ten participants with the most and least significant changes in depression levels will be selected for an open-ended questionnaire.
Study NCT04703764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily, 14-day multiple oral administration
Study NCT04703764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily, 14-day multiple oral administration
Study NCT05717192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InterVapor®-System
Description: The InterVapor System uses heated water vapor to ablate the airways and parenchyma within targeted regions of the lung. Lung remodeling occurs after an initial localized inflammatory response and a subsequent healing and repair. The remodeling of the tissue results in reductions in tissue and air volume in the targeted regions of the lung. The remodeled lung tissue does not re-inflate as a result of collateral ventilation.~The lung volume reduction of diseased hyper-inflated lung segments after InterVapor treatment is expected to increase elastic recoil by reducing the most compliant segments of the lung, decompressing segments of healthier lung allowing for alveolar recruitment, and improving the mechanical efficiency of the respiratory muscles. These mechanical changes are anticipated to improve pulmonary function, exercise capacity and quality of life.
Study NCT04659616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04659616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow biopsy and aspirate
Study NCT04659616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiratie
Study NCT04659616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT04659616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV
Study NCT04659616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiography
Description: Undergo ECHO
Study NCT04659616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Given PO
Study NCT05248659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibeprenlimab 400 mg s.c. Q4weeks
Description: Sibeprenlimab 400 mg s.c. q 4 weeks
Study NCT06645470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care (SMC)
Description: Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
Study NCT06645470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Care (SMC)
Description: Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
Study NCT06645470 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Contacts
Description: Participants will receive contacts with the research staff at weeks 6, 12, and 18.
Study NCT06645470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring Contacts
Description: Participants will receive contacts with the research staff at weeks 6, 12, and 18.
Study NCT06645470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Aerobic Training will be supervised exercise. It will occur on 3 days per week and will progress to 50 minutes per session (150 minutes per week). The intensity of the exercise will progress from 60%±5% to 70%±5% of age-predicted maximal heart rate (if taking beta-blocker medication intensity will progress from a Rating of Perceived Exertion of 11-13 to 12-14 based on the 6-20 Borg scale). While walking will be the preferred mode of exercise, alternative forms of cardiovascular exercise (upright cycling, elliptical, etc.) are allowed to accommodate any physical limitations that may be present for a participant. Heart rate will be monitored throughout these exercise sessions.
Study NCT06645470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Resistance Training will be supervised exercise. It will occur 3 days per week and includes 8 exercises performed in a prespecified order. Week 1-2 sessions focus on familiarization to acclimate the participant to the equipment, proper form, to establish initial weight (load) for training, and with performing multiple sets per day. For Weeks 3-8, participants will engage in 2 sets per exercise with the weight adjusted to elicit muscle fatigue in 8-12 repetitions per set. This progresses to 3 sets per exercise from Week 9 until the end of the intervention period. When 12 repetitions for a specific exercise can be achieved, the resistance will increase for that exercise at the next session. There is a 90 second rest period between each set of an exercise. Heart rate will be monitored throughout these exercise sessions.
Study NCT06645470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: A single counseling session to discuss the dietary recommendations when taking an obesity medication.
Study NCT06645470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: A single counseling session to discuss the dietary recommendations when taking an obesity medication.
Study NCT05683834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matrix-M1 Adjuvant
Description: Matrix-M1 is composed of 2 types of 40 nm-sized particles each with a different saponin fraction (fraction A and fraction B) combined with cholesterol and phospholipid.
Study NCT05683834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBV gp350-Ferritin Vaccine
Description: The EBV gp350-Ferritin vaccine is composed of Helicobacter pylori non-heme ferritin fused to EBV gp350 which self-assembles to form a nanoparticle. The vaccine is supplied in single-use vials at a concentration of 250 micrograms/mL in 1.7 mM KH2PO4, 5 mM Na2HPO4, 150 mM NaCl, 5% sucrose, pH 7.4 (diluent).
Study NCT05683834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Normal Saline
Study NCT04647240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dermacyte® Liquid (human amniotic fluid)
Description: Subcutaneous injection into and/or around wound bed weekly
Study NCT04647240 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Dermacyte® Liquid (human amniotic fluid)
Description: Subcutaneous injection into and/or around wound bed weekly
Study NCT06474494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Application of one layer
Description: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying one layer of Scotchbond Universal Plus adhesive
Study NCT06474494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of double layer
Description: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying double layer of Scotchbond Universal Plus adhesive
Study NCT04485104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Oral Solution
Study NCT06230822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VUM02 Injection
Description: VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.
Study NCT06474494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Etch-and-rinse application mode
Description: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as etch-and-rinse application mode
Study NCT06474494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse application mode
Description: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as etch-and-rinse application mode
Study NCT04366895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional single implant overdenture
Description: conventional manufactured implant overdenture
Study NCT05746195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention via Text Messaging
Description: Text messages will be sent to participants cell phones using the HealthySMS platform
Study NCT05746195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Various questionnaires evaluating participants dietary habits and use of study intervention will be administered
Study NCT05746195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Participants will receive nutrition education materials
Study NCT04191590 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: nasal brushing and bacteriological sample
Description: A nasal brushing as well as a bacteriological sample using a swab under general anesthesia at the beginning of the endonasal surgery procedure
Study NCT04366895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3d printed single implant overdenture
Description: CAD-CAM manufactured implant overdenture.
Study NCT06474494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective enamel etching application mode
Description: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as selective enamel etching mode
Study NCT06474494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective enamel etching application mode
Description: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as selective enamel etching mode
Study NCT05457504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote blood pressure monitoring
Description: Participants assigned to this arm will participate in the experimental intervention
Study NCT05457504 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants assigned to this arm will participate in a placebo intervention
Study NCT04913558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The exercise will be performed by using the treadmill as the following:~- The first stage (warming up): It consists of 5 minutes warming up with the treadmill speed set at 1.0 mile per hour.~- The second stage (active stage): It consists of 20 minutes with the treadmill speed set at 3.0 miles per hour.~- Third stage (cooling down): It consists of 5 minutes of cooling down with the treadmill speed set at 1.0 miles per hour.
Study NCT04913558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Treatment
Description: 1. General advice for reducing fatigue and stress~2. Fluid and diet advice~3. Carrying the Baby~4. While Breastfeeding in a sitting position~5. Selecting Clothing
Study NCT04913558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Treatment
Description: 1. General advice for reducing fatigue and stress~2. Fluid and diet advice~3. Carrying the Baby~4. While Breastfeeding in a sitting position~5. Selecting Clothing
Study NCT05383183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Alfoscerate 400mg
Description: Oral administration
Study NCT05383183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT06502782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: digital assesment
Description: Gingival recession sites were scanned with an intraoral optical surface scanner, and STL images were recorded. The images were imported into image analysis software. The depth, width and area of gingival recession were calculated using Autocat program.
Study NCT05109624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prolonged prone position ventilation
Description: patients mechanically ventilated with SARS COV 2 will be subjected to a longer than usual period of prone position ventilation
Study NCT04867733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micropatch (microneedle patch)
Description: Each micropatch contains an array of 50 microneedles.
Study NCT05088057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg on Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles (Q3W), intravenous (IV) infusion.
Study NCT05088057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
Study NCT05088057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
Study NCT04828746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Skin Marking
Description: Using ultrasound for skin marking pre-procedure
Study NCT06514638 — intervention group
Intervention type: OTHER
Intervention: Ultrasound imaging
Description: Images of the vastus medialis were taken with the subject being lateral decubitus.
Study NCT05088057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m² on Day 1 of Cycles 1-4 (Q3W) or Cycles 5-8 (Q3W) of the neoadjuvant phase of the study, IV infusion;
Study NCT06097663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825
Description: Active MAS825 single dose
Study NCT06097663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825 Placebo
Description: MAS825 placebo single dose
Study NCT06097663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAS825 Placebo
Description: MAS825 placebo single dose
Study NCT06097663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: Oral tablet of DFV890 active once daily
Study NCT06097663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890 placebo
Description: Oral tablet of DFV890 placebo once daily
Study NCT06097663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DFV890 placebo
Description: Oral tablet of DFV890 placebo once daily
Study NCT06141447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin + normal saline
Description: 40 units IV oxytocin once in a 1000 mL bag of normal saline
Study NCT06141447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 1000 mL bag of normal saline alone
Study NCT05711134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback on Individual Practice Patterns
Description: Providers are given feedback on their practice patterns of ordering computed tomography of the cervical spine.
Study NCT05900544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: System implementation of patient-centered incidental findings report
Description: For three lung cancer screening programs a system level implementation for a patient-centered incidental findings report
Study NCT03825302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Methacholine challenge
Description: Methacholine inhalation challenge will be administered to both male and females with asthma
Study NCT03825302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mannitol challenge
Description: Mannitol inhalation challenge will be administered to both male and females with asthma
Study NCT05010980 — intervention group
Intervention type: OTHER
Intervention: CMR
Description: clinical indication
Study NCT05010980 — intervention group
Intervention type: OTHER
Intervention: scintigraphy
Description: clinical indication
Study NCT05007756 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVB Challenge
Description: UVB challenge will be administered dermally through Lumera Phototherapy System.
Study NCT05282771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%
Description: The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
Study NCT05282771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%
Description: The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
Study NCT05282771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
Study NCT04976686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: Participants will reduce their carbohydrate consumption to 80g daily
Study NCT04520971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 780G
Description: 780G closed-loop insulin delivery system (Medtronic)
Study NCT04520971 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: continue with standard of care treatment (pump without closed-loop or MDI)
Study NCT05938075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXCO-100
Description: Sterile suspension for injection
Study NCT05938075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine
Description: Sterile suspension for injection
Study NCT05566028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D745 formulation I
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
Study NCT05566028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D745 formulation II
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
Study NCT05566028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D745 Placebo
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
Study NCT04566120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinnamon extract mouthwash
Description: cinnamon extract mouthwash